SANUWAVE Health, Inc. Hits New 52-Week Low at $19.55

SANUWAVE Health, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 19.55 as of March 20, 2026. This significant decline highlights the stock's recent performance, contrasting sharply with its 52-week high of USD 46.59. The company's market capitalization stands at approximately USD 190 million, reflecting its microcap status. Financial metrics indicate a price-to-earnings (P/E) ratio of 46.00, while the return on equity is notably low at -999,999.00%. Additionally, SANUWAVE Health has a price-to-book ratio of -64.94, suggesting challenges in asset valuation. With a dividend yield of 0.00% and a debt-to-equity ratio of -4.76, the company appears to be navigating a complex financial landscape. Over the past year, SANUWAVE Health's performance has been notably below that of the S&P 500, which has seen a 14.9% increase. This recent low may prompt further scrutiny of the company's operational strategies and market positioning.